ArticleJournal for immunotherapy of cancer2023

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).

Bilal A Siddiqui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.